Black coffee steaming on my desk, Federal Circuit opinions piling up like unread emails from VCs peddling the next big nothing.
CAFC rejects untimely expert testimony. That’s the headline grabbing me first from this week’s IP roundup — straight out of Trudell Medical International v. D R Burton Healthcare. District Judge Terrence Boyle in Eastern North Carolina let in an expert report on noninfringement that showed up fashionably late, post-discovery deadline. Federal Rule of Civil Procedure 26 doesn’t play that game, and neither does the appellate court.
They reversed. Hard.
Remanded the case — but not back to Boyle. Nope. Reassigned to a new judge entirely, thanks to some off-the-cuff remarks from the bench that screamed bias. The CAFC didn’t mince words: those statements “undermined the appearance of justice and fairness.” Imagine that — a judge’s snark tanking impartiality in a high-stakes patent spat.
Here’s the money quote from the ruling:
“The district court’s comments created an appearance of bias that undermined public confidence in the fairness of the proceedings.”
Why Reassign the Case? A Rare CAFC Move
Look, reassignments aren’t everyday CAFC fare. This one’s got teeth because Boyle’s comments weren’t subtle — think along the lines of dismissing one side’s arguments with a judicial eye-roll. I’ve covered enough district court dramas over two decades to know: when appeals courts step in like this, it’s a signal. Eastern NC’s patent docket just got a wake-up call.
And who’s cashing in? Defendants like D R Burton, maybe, buying time on remand. Plaintiffs? Trudell Medical’s breathing fire over lost momentum. But the real winners — the procedural sticklers, the discovery police who thrive on technical knockouts. Patent litigation’s already a war of attrition; this amps the paperwork Armageddon.
My unique spin: this echoes the 2010s PTAB shakeups, when director bias claims led to en banc reviews. History rhymes — expect more scrutiny on bench behavior as AI tools start parsing transcripts for sentiment. Bold prediction: by 2026, we’ll see software flagging “appearance of bias” in real-time, turning judges into graded performers.
Short para for punch: Cynical? Yeah. But judges aren’t infallible.
Shift gears to biotech brawn. Wuhan Healthgen Biotechnology v. ITC — recombinant human serum albumin (rHSA) patents hold firm. Imports from China tested clean under 2% aggregated albumin stateside? Doesn’t matter. CAFC says evidence from China suffices; transport doesn’t magically spike aggregates. Ventria Biosciences’ Optibumin domestic industry prong? Affirmed, despite tiny market slice. Investment-to-revenue ratios rule the day.
Who profits? Small biotechs like Ventria, shielding niches from offshore knockoffs. Big Pharma watches, licking chops — Section 337 ITC actions just got a green light for global supply chain policing.
Does rHSA Ruling Greenlight More ITC Import Bans?
Absolutely. Critics whine about protectionism, but here’s the rub: without it, U.S. innovation starves. Europe’s EPO chimes in with a study — they lead U.S. in oncology startups sheer numbers. Outpace? Sure, but quality? Patents filed don’t mean cures brewed. America’s still the cash cow; Europe’s the quantity printer.
PTAB obviousness upheld in HD Silicon Solutions v. Microchip. Claim construction goofed — “comprising tungsten” meant elements, not compounds — but prior art covered it anyway. HD Silicon’s IC patent bites dust. Obviousness lives.
Ninth Circuit: copyright inheritors via will dodge termination notices statutory heirs face. Wills trump statute — estate planners rejoice.
Europe’s turn. CJEU Advocate General Maciej Szpunar opines: online marketplaces like Russmedia’s aren’t GDPR violators if they’re neutral processors. No duty to pre-check every ad’s personal data — images, phone numbers included. Provided they don’t curate content.
“Operators of online marketplaces may be exempt from liability as to the contents of ads published on their websites without being obliged to systematically check ad content.”
Are Online Marketplaces Truly GDPR-Safe Now?
Neutral? Please. Platforms love that loophole — it’s why Facebook Marketplace thrives, hands washed of seller sins. But skeptics (me included) smell spin. Enforcement agencies won’t buy “we’re just pipes” forever; expect national tweaks post-CJEU ruling.
Historical parallel: U.S. Section 230 immunity — born noble, bloated into shield for malice. GDPR’s neutrality carveout? Same trajectory, unless regulators claw back.
And the bark? Senator Thom Tillis helms Senate IP Subcommittee again — GOP steady hand on patents. Plus, IPWatchdog’s Luna expecting six German Shorthaired Pointer pups. Adorable video of belly wiggles? Sure. But in IP world, puppies = distraction from real bites.
I’ve chased Valley hype for 20 years — unicorns birthed in garages, now patent pups? Cute. Who’s monetizing? IPWatchdog’s merch empire, probably.
Dense dive: Tillis matters because 119th Congress eyes patent reform. Post-America Invents Act scars linger; expect Big Tech lobbying to kneecap trolls while biotechs beg for stability. Oncology startup surge in Europe? U.S. counters with tax credits, but Europe’s grant gravy train pulls ahead. Numbers game — until clinical trials cull the herd.
Copyright termination twist: wills bypass notices. Family feuds over Beatles catalogs? Less messy now. Executors sleep easier.
One-sentence wonder: IP law grinds on.
Wrapping the week’s essence — procedural purity reigns, platforms exhale, biotechs bunker down. But ask: who foots the bill? Litigants bleed cash; VCs bet on survivors.
Why Does This Matter for Patent Litigators?
Deadlines are sacred; judges, muzzled. ITC’s your friend for imports. Obviousness? Prior art’s king, construction be damned.
Sprawling thought: In a world where AI drafts claims overnight, human judges police the chaos — but bias creeps, neutrality frays. Twenty years in, I’m betting the house: procedural wins outpace merits 3:1. Money’s in the motions, not the molecules.
Puppies incoming. Stay tuned.
🧬 Related Insights
- Read more: Meta Ditches Mercor After Breach Cracks Open AI’s Data Black Box
- Read more: Cindy Cohn’s 30-Year War on Digital Surveillance Comes to D.C.—And It’s Not Over
Frequently Asked Questions
What happened in Trudell Medical v. D R Burton? CAFC reversed admission of an untimely expert report on noninfringement and reassigned the case due to judge bias appearances.
Do online marketplaces have to check ads under GDPR? No, if they’re neutral processors without systematic content review duties, per CJEU AG opinion.
Does the rHSA case change ITC import rules? It affirms testing abroad counts for infringement if products don’t change in transit, bolstering complainant domestic industry proofs.
